HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents

D Palmieri1, T Valentino, D D'Angelo

  • 1Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli Federico II, Naples, Italy.

Oncogene
|February 23, 2011
PubMed

Insights

High-mobility group A (HMGA) proteins regulate ATM gene expression, impacting DNA damage response. Inhibiting HMGA enhances cancer cells

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • DNA-damaging therapies are crucial for cancer treatment but face resistance from specific cancer cell populations.
  • High-mobility group A (HMGA) proteins are implicated in cell transformation and are overexpressed in many cancers, correlating with poor prognosis and drug resistance.
  • Ataxia-telangiectasia mutated (ATM) is the primary cellular sensor of genotoxic stress.

Purpose of the Study:

  • To investigate the relationship between HMGA proteins and ATM in the context of DNA damage response.
  • To explore the role of HMGA proteins in regulating ATM gene expression and its impact on cancer drug resistance.

Main Methods:

  • Investigated HMGA1 and HMGA2 as substrates of ATM.
  • Analyzed HMGA proteins' effect on ATM gene expression using promoter activity assays.
  • Studied the impact of HMGA inhibition on ATM levels, DNA damage response, and sensitivity to DNA-damaging agents in cell models.

Main Results:

  • HMGA2 was identified as a novel substrate of ATM.
  • HMGA proteins positively regulate ATM gene expression, forming a positive feedback loop modulated by DNA damage and ATM activity.
  • Inhibition of HMGA expression reduced ATM protein levels, impaired DNA damage response, and increased sensitivity to DNA-damaging agents.

Conclusions:

  • A novel HMGA-ATM pathway has been identified, crucial for regulating the DNA damage response.
  • This pathway represents a potential therapeutic target to overcome resistance to genotoxic anti-cancer drugs.
  • Targeting HMGA could enhance the efficacy of conventional cancer treatments in resistant tumors.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: